HUE027169T2 - Komplement antagonisták és azok alkalmazása - Google Patents
Komplement antagonisták és azok alkalmazása Download PDFInfo
- Publication number
- HUE027169T2 HUE027169T2 HUE09788222A HUE09788222A HUE027169T2 HU E027169 T2 HUE027169 T2 HU E027169T2 HU E09788222 A HUE09788222 A HU E09788222A HU E09788222 A HUE09788222 A HU E09788222A HU E027169 T2 HUE027169 T2 HU E027169T2
- Authority
- HU
- Hungary
- Prior art keywords
- oligomer
- rna
- lna
- seq
- nucleotide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (4)
- S» Oligomer a 2. igénypont szerint* ahol a módosítóit tatern-ukleozld kötés egy foszfort*oát huenm kieozkl kötés, ő. Oligomer a 2. Igénypont szerinL ahol a módosított oukleobázis az őmteíihebozm,7, Oligomer az I , igénypont szeriek ahol az oligomer 12~?ői 45ág mtkieotld hosszúságii8, CMIgomer az i. igénypont szerint, ahol az oligomer í 0-től 18-ig nukleotkl hosszúságú. % Oligomer az 1. igénypont szerint, ahol az oligomer a 132, 453,. 566, /26 vagy 1035 mmleotkiokra van irányítva a SEQ ID NO: I -nek az ΛΤΟ start helyéből, I#. Oligomer az L vagy 9, igénypont szerint, ahol az oligomer legalább 90'%-os, 5X>%-os, 97%-os, 98%-os vagy 99%-os szekvencia-identitással rendelkezik a Komplement-Kotoponerts €Ö szekvenciához viszonyítva, amely a SEQ ID NO: 1 által van képviselve, Π. Gyóg yszerészeti készítmény, amely tartalmazza az L vagy 2, igénypont szerinti oiigomeo és egy gyógyszerészeti leg elfogadható Mgitét, hordozol sőt vagy adjuvánst. .12, Legalább egy az, i, igénypont szeriinti oligomer alkalmazása egy gyógyszernek az előállítása céljából egy állapotnak a kezelésére, amely axonáiis regenerációt igényel, 13» Legalább egy az: !, igénypont szerinti oligomer alkalmazása egy gyógyszernek az előállítása céljából egy kréniknsdemielMzáC'iás állapot, kezelésére, 14 Alkalmazás a 1B. igénypont szerint, ahol a krónikus demieiinixacios állapot a szklerózis multiplex, egy krónikus detmeiinrzádos neto'opartu, iá és IB típusú liMSN (CMT) betegség, Aizhelmemkőr, iitmtingion-kor, Charcoi-Marté-Tooíh betegség, amioirolMs lateráiszklerózis ( A11..S}, Gtuilam-Barre szindróma (G 88.. amely szintén .ismert a km gyulladásos deoueiiuizáctős polmeuropáíta vagy A1DP), leofeodtsziróíta vagy Parkinson· kór. KOMPLEMENT ANTAGONISTÂK ÉS AZOK ALKALMAZÁSA. Szabadalmi igény pirítok P .Egyszálú aotiszensz oligomer, amely 10-tél 5ö-ig' npkjeotid hosszúságú, és amely rendelkezik egy összefüggő rmkleobázis-szekvenelával, amely legalább 80%-os szekvencia-identitással rmlelkezlk egy nukleiosav egy komplementer régiójához viszonyítva, amely kódolja a KOMFIJ'IA^:iNTKOMIX)NÉNS 6 (€6) szekvenciát, amely a SEQ ID NO; l által van képviselve; ahol az oligomer tartalmaz legalább egy nukleont! analógot és képes arra, hogy a €6 mRNS expressziónak a szintje legyen csökkentve egy emlősben legalább 20%-ak ahogyan az egy qfÇR-vizsgálat révén van meghatározva, ahol az oligomer az 112-152, 433-473, 546-586, 706-746, vagy 1015-1055 nukleoüdokra van irányítva a SEQ !D NO; 1-nek az A TG start helyéből
- 2, Oligomer az L igénypont szerint, ahol az oligomer továbbá tartalmazza legalább az egyiket egy Módosított irrternukleozid kötés és egy módosított. nnkleobázis kőzni.
- 3, Oligomer az i, igénypont szerint,, ahol a nukkobd analóg egy módosított cukor-rész, amely a. következőknél álló csoportból van választva; egy 2'-0-tnetoxl-etil módosított cukor-rész, egy T’-metoxi módosított cukor-rész, egy 2'-0- atkái módosított cukor-rész és egy bi ciklusos ott kor-rész,
- 4, Obgomer a 3. igénypont szerint, ahol a biciilusos cukor-rész egy zárt nukleinsav (LNA, angolul; „locked nucleic ackP) monomer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7950108P | 2008-07-10 | 2008-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE027169T2 true HUE027169T2 (hu) | 2016-10-28 |
Family
ID=41507609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE09788222A HUE027169T2 (hu) | 2008-07-10 | 2009-07-10 | Komplement antagonisták és azok alkalmazása |
Country Status (18)
Country | Link |
---|---|
US (2) | US8703730B2 (hu) |
EP (1) | EP2320925B1 (hu) |
JP (1) | JP2011527568A (hu) |
KR (1) | KR20110044983A (hu) |
CN (2) | CN103740713A (hu) |
AU (1) | AU2009270020B2 (hu) |
CA (1) | CA2730203C (hu) |
CY (1) | CY1117476T1 (hu) |
DK (1) | DK2320925T3 (hu) |
ES (1) | ES2566008T3 (hu) |
HR (1) | HRP20160261T1 (hu) |
HU (1) | HUE027169T2 (hu) |
IL (1) | IL210506A (hu) |
NZ (1) | NZ591057A (hu) |
PL (1) | PL2320925T3 (hu) |
SI (1) | SI2320925T1 (hu) |
SM (1) | SMT201600098B (hu) |
WO (1) | WO2010005310A2 (hu) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
US20130047297A1 (en) | 2010-03-08 | 2013-02-21 | Robert D. Sammons | Polynucleotide molecules for gene regulation in plants |
MX343072B (es) | 2011-09-13 | 2016-10-21 | Monsanto Technology Llc | Metodos y composiciones para controlar malezas. |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
BR112014005979A8 (pt) | 2011-09-13 | 2017-09-12 | Monsanto Technology Llc | Métodos e composições quimicas agricolas para controle de planta, método de redução de expressão de um gene ppg oxidase em uma planta, cassete de expressão microbiana, método para fazer um polinucleotídeo, método de identificação de polinucleotídeos úteis na modulação de expressão do gene ppg oxidase e mistura herbicida |
MX350773B (es) | 2011-09-13 | 2017-09-15 | Monsanto Technology Llc | Métodos y composiciones para el control de malezas. |
MX348495B (es) | 2011-09-13 | 2017-06-14 | Monsanto Technology Llc | Metodos y composiciones para el control de malezas. |
CN103957697B (zh) | 2011-09-13 | 2017-10-24 | 孟山都技术公司 | 用于杂草控制的方法和组合物 |
WO2013040005A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
BR112014005951A2 (pt) | 2011-09-13 | 2017-04-04 | Monsanto Technology Llc | métodos e composições para controle de erva daninha |
BR112014005975A8 (pt) | 2011-09-13 | 2017-09-12 | Monsanto Technology Llc | Método de controle de planta, método de redução de expressão de um gene pds em uma planta, cassete de expressão microbiana, método de fazer um polinucleotídeo, método de identificação de polinucleotídeos, e composições para controle de erva daninha |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9192651B2 (en) * | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
EP3604536B1 (en) | 2012-04-23 | 2024-05-29 | Vico Therapeutics B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders |
AR091143A1 (es) | 2012-05-24 | 2015-01-14 | Seeds Ltd Ab | Composiciones y metodos para silenciar la expresion genetica |
DK2897454T3 (da) | 2012-09-24 | 2020-01-20 | Seminis Vegetable Seeds Inc | Fremgangsmåder og sammensætninger til forlængelse af planteprodukters holdbarhed |
US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
WO2014096958A1 (en) | 2012-11-02 | 2014-06-26 | Academisch Medisch Centrum | Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders |
BR112015010116A2 (pt) | 2012-11-15 | 2017-08-22 | Roche Innovation Ct Copenhagen As | COMPOSTOS CONJUGADOS ANTI-SENTIDO ANTI-ApoB |
EP2941487A2 (en) | 2013-01-01 | 2015-11-11 | A.B. Seeds Ltd. | ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
MX360273B (es) | 2013-01-15 | 2018-10-26 | Monsanto Technology Llc | Metodos y composiciones para el control de plagas en plantas. |
CA2893801A1 (en) | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
CA2905104A1 (en) | 2013-03-13 | 2014-10-09 | Monsanto Technology Llc | Control of lolium species by topical application of herbicidal composition comprising dsrna |
EP3604535A3 (en) | 2013-03-13 | 2020-04-22 | Monsanto Technology LLC | Methods and compositions for weed control |
US20140283211A1 (en) | 2013-03-14 | 2014-09-18 | Monsanto Technology Llc | Methods and Compositions for Plant Pest Control |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
BR112016000555B1 (pt) | 2013-07-19 | 2022-12-27 | Monsanto Technology Llc | Método para controlar uma infestação da espécie de leptinotarsa em uma planta, composição inseticida e construção de dna recombinante |
WO2015038939A2 (en) * | 2013-09-13 | 2015-03-19 | Isis Pharmaceuticals, Inc. | Modulators of complement factor b |
AU2014341879B2 (en) | 2013-11-04 | 2020-07-23 | Beeologics, Inc. | Compositions and methods for controlling arthropod parasite and pest infestations |
UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
CN105979770B (zh) | 2014-01-15 | 2019-07-05 | 孟山都技术公司 | 用于使用epsps多核苷酸的杂草控制的方法和组合物 |
US11091770B2 (en) | 2014-04-01 | 2021-08-17 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
CA2943894A1 (en) | 2014-05-01 | 2015-11-05 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating complement factor b expression |
WO2015200223A1 (en) | 2014-06-23 | 2015-12-30 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via rna interference |
US11807857B2 (en) | 2014-06-25 | 2023-11-07 | Monsanto Technology Llc | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
AU2015296700B2 (en) | 2014-07-29 | 2021-10-21 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
CN113563468A (zh) | 2014-12-19 | 2021-10-29 | 雷根尼桑斯公司 | 结合人c6的抗体及其用途 |
WO2016118007A1 (en) | 2015-01-21 | 2016-07-28 | Regenesance B.V. | Means and methods for counteracting complement-mediated hemolytic anemia |
EP3256589B1 (en) | 2015-01-22 | 2021-12-22 | Monsanto Technology LLC | Compositions and methods for controlling leptinotarsa |
WO2016196738A1 (en) | 2015-06-02 | 2016-12-08 | Monsanto Technology Llc | Compositions and methods for delivery of a polynucleotide into a plant |
US10655136B2 (en) | 2015-06-03 | 2020-05-19 | Monsanto Technology Llc | Methods and compositions for introducing nucleic acids into plants |
MA43072A (fr) * | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
EP3748003A1 (en) | 2016-01-26 | 2020-12-09 | Monsanto Technology LLC | Compositions and methods for controlling insect pests |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030096775A1 (en) * | 2001-10-23 | 2003-05-22 | Isis Pharmaceuticals Inc. | Antisense modulation of complement component C3 expression |
EP2305812A3 (en) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
JPWO2005116204A1 (ja) * | 2004-05-11 | 2008-06-19 | 株式会社アルファジェン | Rna干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
JP2009514888A (ja) * | 2005-11-04 | 2009-04-09 | ジェネンテック・インコーポレーテッド | 眼疾患を処置するための補体経路の阻害剤の使用 |
WO2007089375A2 (en) * | 2005-12-22 | 2007-08-09 | Exegenics, Inc. D/B/A Opko Health, Inc. | Compositions and methods for regulating complement system |
HUE026042T2 (hu) * | 2006-10-10 | 2016-05-30 | Regenesance B V | Komplement gátlás javított idegregeneráció céljából |
-
2009
- 2009-07-10 US US13/003,062 patent/US8703730B2/en active Active
- 2009-07-10 CN CN201310576286.3A patent/CN103740713A/zh active Pending
- 2009-07-10 SI SI200931393A patent/SI2320925T1/sl unknown
- 2009-07-10 HU HUE09788222A patent/HUE027169T2/hu unknown
- 2009-07-10 WO PCT/NL2009/050418 patent/WO2010005310A2/en active Application Filing
- 2009-07-10 PL PL09788222T patent/PL2320925T3/pl unknown
- 2009-07-10 EP EP09788222.9A patent/EP2320925B1/en active Active
- 2009-07-10 KR KR1020117001948A patent/KR20110044983A/ko not_active Application Discontinuation
- 2009-07-10 CN CN2009801354301A patent/CN102149390A/zh active Pending
- 2009-07-10 CA CA2730203A patent/CA2730203C/en active Active
- 2009-07-10 NZ NZ591057A patent/NZ591057A/xx unknown
- 2009-07-10 DK DK09788222.9T patent/DK2320925T3/en active
- 2009-07-10 JP JP2011517368A patent/JP2011527568A/ja active Pending
- 2009-07-10 ES ES09788222.9T patent/ES2566008T3/es active Active
- 2009-07-10 AU AU2009270020A patent/AU2009270020B2/en active Active
-
2011
- 2011-01-06 IL IL210506A patent/IL210506A/en active IP Right Grant
-
2014
- 2014-03-12 US US14/206,022 patent/US9089555B2/en active Active
-
2016
- 2016-03-14 HR HRP20160261TT patent/HRP20160261T1/hr unknown
- 2016-03-23 CY CY20161100247T patent/CY1117476T1/el unknown
- 2016-04-05 SM SM201600098T patent/SMT201600098B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010005310A3 (en) | 2010-04-15 |
EP2320925A2 (en) | 2011-05-18 |
CN102149390A (zh) | 2011-08-10 |
US20110171176A1 (en) | 2011-07-14 |
CA2730203A1 (en) | 2010-01-14 |
US8703730B2 (en) | 2014-04-22 |
NZ591057A (en) | 2012-11-30 |
SMT201600098B (it) | 2016-04-29 |
US20140301982A1 (en) | 2014-10-09 |
AU2009270020B2 (en) | 2014-09-25 |
AU2009270020A2 (en) | 2011-01-27 |
IL210506A (en) | 2015-06-30 |
ES2566008T3 (es) | 2016-04-08 |
EP2320925B1 (en) | 2015-12-23 |
HRP20160261T1 (hr) | 2016-06-03 |
CA2730203C (en) | 2016-12-13 |
CY1117476T1 (el) | 2017-04-26 |
US20150211003A9 (en) | 2015-07-30 |
US9089555B2 (en) | 2015-07-28 |
SI2320925T1 (sl) | 2016-05-31 |
CN103740713A (zh) | 2014-04-23 |
IL210506A0 (en) | 2011-03-31 |
JP2011527568A (ja) | 2011-11-04 |
WO2010005310A2 (en) | 2010-01-14 |
PL2320925T3 (pl) | 2016-06-30 |
KR20110044983A (ko) | 2011-05-03 |
AU2009270020A1 (en) | 2010-01-14 |
DK2320925T3 (en) | 2016-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9089555B2 (en) | Complement antagonists and uses thereof | |
US10912792B2 (en) | Compounds and methods for modulating angiotensinogen expression | |
US8921331B2 (en) | Methods for slowing familial ALS disease progression | |
JP6538736B2 (ja) | Gcgr発現のアンチセンス調整 | |
US20110237646A1 (en) | Modulation of transthyretin expression for the treatment of cns related disorders | |
US9796976B2 (en) | Methods and compositions for modulating alpha-1 antitrypsin expression | |
JP2015501155A (ja) | Gccr発現のアンチセンス調整 | |
US20210000906A1 (en) | Modulation of hsd17b13 expression | |
CN111394355A (zh) | 促血管生成素样3表达的调节 | |
JP2019525918A (ja) | Smn2の調節のための化合物及び方法 | |
KR20230076823A (ko) | 시신경 위축의 치료 | |
WO2011105902A2 (en) | Antagonists of complement component 8-beta (c8-beta) and uses thereof | |
WO2011105900A2 (en) | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof | |
WO2011105901A2 (en) | Antagonists of complement component 9 (c9) and uses thereof | |
AU2014280940A1 (en) | Complement antagonists and uses thereof | |
US20220282257A1 (en) | Method of modulating adiposity | |
CA2530108A1 (en) | Oligonucleotide inhibitors of mbd2/dna demethylase and uses thereof | |
TW202016305A (zh) | Apol1表現之調節劑 | |
WO2013142509A1 (en) | ANTISENSE MODULATION OF HYPOXIA INDUCIBLE FACTOR 1 ALPHA (HIFIα) EXPRESSION |